Rapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors
Burlington, Ontario--(Newsfile Corp. - June 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated May 10, 2025, it has entered into debt settlement agreements with certain of its creditors (the "Creditors") to issue an aggregate of 1,888,237 common shares (the "Settlement Shares") to such Creditors in exchange for the cancellation of outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of $377,647.50 (the "Debt")...
2025-06-02 9:10 AM EDT
Rapid Dose Announces Proposed Equity Private Placement Financing
Burlington, Ontario--(Newsfile Corp. - May 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to $3,000,000 of gross proceeds, consisting of up to 13,636,364 units (the "Units") at a price of $0.22 per Unit. Each Unit will consist of one (1) common share of the Company (a "Common Share") and one (1) common share purchase warrant of the...
2025-05-27 5:03 PM EDT
Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery Technology
Burlington, Ontario--(Newsfile Corp. - May 26, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips-representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster...
2025-05-26 6:09 PM EDT
Rapid Dose Announces Proposed Debt Settlement
Burlington, Ontario--(Newsfile Corp. - May 9, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces that it has agreed with certain of its creditors (the "Creditors") to issue up to an aggregate of 2,500,000 common shares (the "Settlement Shares") to such Creditors in exchange for the cancellation of outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of up to $500,000 (the "Debt") owing to such Creditors. The Settlement Shares will be issued...
2025-05-09 6:27 PM EDT
Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce an update to the ongoing collaboration project with the Faculty of Kinesiology & Health Studies at the University of Regina on their National Football League (NFL) - funded medical cannabis research project to examine the effects of cannabinoids on sport concussion and pain management....
2025-04-08 9:02 AM EDT
Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada
Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce its participation at major dental tradeshows across Canada to showcase and provide samples of an oral dissolving thin film strip called XyliStrip, powered by QuickStrip.QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including...
2025-04-03 5:40 PM EDT
Rapid Dose Therapeutics Corp. Announces Payment in Shares for Quarterly Interest on Secured Debt and Update on Shares for Debt Settlement with Creditors
Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), and consistent with prior quarters, the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on March 31, 2025 under the terms of the Notes. The Company expects to issue the Common Shares...
2025-04-01 9:09 PM EDT
Rapid Dose Therapeutics Corp Announces Proposed Equity Private Placement Financing
Burlington, Ontario--(Newsfile Corp. - February 18, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to $5,000,000 of gross proceeds, consisting of up to 20,833,333 common shares (the "Common Shares") at a price of $0.24 per Common Share.The Company will be engaging Meadowbank Asset Management Inc. (the "Agent") in respect of the Financing. The Agent shall be entitled to...
2025-02-18 5:34 PM EST
Rapid Dose Therapeutics Advances Collaboration with Global Leader for Market-Ready QuickStrip(R) Nicotine in 2025
Burlington, Ontario--(Newsfile Corp. - January 28, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This agreement aims to finalize the development of innovative, market-ready products projected for launch in 2025. The pre-commercialization agreement requires RDT to provide project management and product development services in exchange for a monthly...
2025-01-28 9:38 PM EST
Rapid Dose Provides Update on Share Issuance in Debt Settlement with Creditors and Proposed Private Placement
Burlington, Ontario--(Newsfile Corp. - January 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated December 9, 2024 (the "Initial Press Release"), announcing a proposed debt settlement (the "Shares for Debt Transaction") with certain of its creditors (the "Creditors") to issue an aggregate of up to 1,600,000 common shares (the "Settlement Shares") at $0.25 per share to such Creditors in exchange for the cancellation of outstanding accounts payable...
2025-01-27 4:30 PM EST
Rapid Dose Completes Issuance of Shares as Payment of Directors' Fees
Burlington, Ontario--(Newsfile Corp. - January 16, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has completed its previously announced shares for debt transaction to issue common shares (the "Debt Shares") to its non-management directors (the "Directors") in exchange for the cancellation of directors' fees owing. Each of the five Directors was owed $10,000 in directors' fees for each of the fiscal quarters ended May 31, August 31 and November...
2025-01-16 8:56 AM EST
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), and consistent with prior quarters, the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on December 31, 2024 under the terms of the Notes. The Company expects to issue the Common Shares no...
2025-01-07 5:16 PM EST
Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees
Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces that it has agreed with its non-management directors (the "Directors") to issue common shares (the "Debt Shares") to such Directors in exchange for the cancellation of director fees owing. Each of the five Directors is owed $10,000 in director fees for each of the fiscal quarters ended May 31, August 31 and November 30, 2024, for an aggregate amount of $150,000...
2024-12-24 8:49 AM EST
Rapid Dose Announces Proposed Equity Private Placement Financing and Proposed Shares for Debt Settlement
Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the "Units") at a price of $0.25 per Unit. Each Unit will consist of one (1) Common Share and one (1) Common Share Purchase Warrant (a "Warrant"). Each Warrant will be exercisable for one (1)...
2024-12-10 4:15 PM EST
Rapid Dose Therapeutics Corp. Files Patent Application for Lidocaine Oral Thin Strip
Burlington, Ontario--(Newsfile Corp. - December 5, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office ("CIPO").Dentists commonly perform dental procedures using anesthesia administered through injection by needle, which is commonly preceded by a spray, gel, jelly, cream, or ointment. RDT is proud to announce a significant breakthrough in the...
2024-12-05 5:24 PM EST
Rapid Dose Announces Closing of Final Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of $542,000.The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.The Financing allowed for a maximum of $6,000,000 of gross proceeds consisting of...
2024-10-30 5:05 PM EDT
Rapid Dose Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - October 1, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2024 under the terms of the Financing and the Notes, and expects to issue the Common Shares no later than October 15,...
2024-10-01 6:19 PM EDT
Rapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - September 16, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the "Financing"), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before October 29, 2024. This previously announced Financing contemplates an aggregate of up to $6,000,000 of gross proceeds consisting of up...
2024-09-16 7:38 PM EDT
Rapid Dose Announces Closing of First Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of $309,000.The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.The Financing allowed for a maximum of $6,000,000 of gross proceeds consisting of up to...
2024-07-22 7:15 AM EDT
Rapid Dose Therapeutics Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on June 30, 2024 under the terms of the Financing and the Notes, and expects to issue the Common Shares no later than July 15,...
2024-07-02 7:25 PM EDT